{
  "docId": "019de070-fa64-77bc-8caf-8d60d9bebc40",
  "docSlug": "35e598705f15db6c29b5dc7bc3a9d06d",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 79 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 24,
  "pageCount": 79,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes footnotes referencing clinical trial data and market statistics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-fa64-77bc-8caf-8d60d9bebc40/24",
  "deckHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40",
  "deckJsonHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40.json",
  "deckAnchorHref": "/decks/019de070-fa64-77bc-8caf-8d60d9bebc40#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.42,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Market Opportunity: Acne is the most common skin problem in the United States, affecting up to 50M Americans. ~$600M topical acne market in the U.S. and Canada",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a36759d1-42c2-452b-b471-9df011b6bafd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.42,
        "y": 0.35
      },
      "kind": "chart",
      "text": "% Change: Inflammatory Lesion Counts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2130cb4-d652-474b-96b1-0a6df67f7937",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.7,
        "y": 0.35
      },
      "kind": "chart",
      "text": "% Change: Non-Inflammatory Lesion Counts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffaa0aec-3797-4f78-8ac2-8bd87ed28cad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.25,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. See Slide 1 for further information on forward-looking statements. 2. Sphingosine 1-phosphate. 3. Exclusive licensing agreement with Mitsubishi Tanabe Pharma. 4. Hepatic encephalopathy. 5. Success defined as 2 grade reduction and clear or almost clear EGSS Inclusion criteria: Minimum moderate severity (Grade 3) on EGSS. 6. American Academy of Dermatology. (2020). Skin conditions by the numbers. 7. Mayo Clinic. (2020). Acne. 8. Evaluate and IQVIA MAT Feb 2021. 9. The remainder of Bausch Health is referred to as “Bausch Pharma” and will assume a new name upon the separation of the Company’s eye health business, Bausch + Lomb.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c624670-1a6a-4792-801a-5f3b15805d52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.38,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Readout of topline results of second of two Phase 3 trials for IDP-126... Completed April 2021. Following the results of a comparative bridging study, expected to submit NDA to the FDA in 2H22. Initiate Amiselimod S1P2 Modulator Phase 2 trial - 1H21. Initiate Phase 3 trial for rifaximin life cycle program RED-C - 2H21. Initiate Phase 2 trial for rifaximin life cycle program including sickle cell - 2H21",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64ec4aef-da54-4698-8e8e-53a0b946df10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Near-term Catalysts: Bausch Pharma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e9b92b0-1c15-489a-b2c7-6c806c090904",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "74c3810e-2a41-4bdd-a409-e63dfb09b40e",
      "evidence": "list/bullet: Readout of topline results of second of two Phase 3 trials for IDP-126... Completed April 2021. Following the results of a comparative bridging study, expected to submit NDA to the FDA in 2H22. Initiate Amis",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 79,
      "from": 21,
      "beatId": "4729803e-b632-425a-8f97-04c24718552b",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The company outlines its strategic plan and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 22,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "89154ab5-9a3d-4174-9970-e706cfacf4b3",
      "evidence": "The company discusses its strategic alternatives and timeline",
      "position": 1,
      "objective": "Why is now the right time for strategic alternatives?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}